Bröker Linda E, Giaccone Giuseppe
Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Eur J Cancer. 2002 Dec;38(18):2347-61. doi: 10.1016/s0959-8049(02)00457-4.
Lung cancer is one of the most frequent causes of cancer deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of cases and no curative treatment is available for the advanced stages of disease (stages III and IV), which comprise the majority of cases. Current treatment regimens with standard chemotherapy offer only a limited survival benefit, and, therefore, the development of new therapeutic strategies is needed. Novel chemotherapeutic drugs such as the epothilones, MEN 10755 and S-1 are being studied in patients with advanced stages of disease. Furthermore, a large number of therapies targeted against critical biological abnormalities in NSCLC are being investigated in clinical trials. The latter approach includes inhibition of growth factors, interference with abnormal signal transduction, inhibition of angiogenesis and gene replacement therapy. Promising results have thus far been obtained with some of these therapies. This review describes the role of new therapeutic agents in the treatment of NSCLC.
肺癌是全球癌症死亡的最常见原因之一。非小细胞肺癌（NSCLC）约占病例的80%，对于疾病的晚期（III期和IV期），目前尚无治愈性治疗方法，而晚期病例占大多数。当前的标准化疗方案仅能提供有限的生存益处，因此，需要开发新的治疗策略。新型化疗药物如埃坡霉素、MEN 10755和S-1正在晚期疾病患者中进行研究。此外，大量针对NSCLC关键生物学异常的疗法正在临床试验中进行研究。后一种方法包括抑制生长因子、干扰异常信号转导、抑制血管生成和基因替代疗法。到目前为止，其中一些疗法已取得了有希望的结果。本综述描述了新治疗药物在NSCLC治疗中的作用。
